These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34018212)

  • 21. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.
    Ma B; Meng H; Tian Y; Wang Y; Song T; Zhang T; Wu Q; Cui Y; Li H; Zhang W; Li Q
    BMC Cancer; 2020 Apr; 20(1):318. PubMed ID: 32293336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
    Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
    Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features.
    Liau JY; Tsai JH; Yuan RH; Chang CN; Lee HJ; Jeng YM
    Mod Pathol; 2014 Aug; 27(8):1163-73. PubMed ID: 24406866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
    Komuta M
    Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MYC determines lineage commitment in KRAS-driven primary liver cancer development.
    D'Artista L; Moschopoulou AA; Barozzi I; Craig AJ; Seehawer M; Herrmann L; Minnich M; Kang TW; Rist E; Henning M; Klotz S; Heinzmann F; Harbig J; Sipos B; Longerich T; Eilers M; Dauch D; Zuber J; Wang XW; Zender L
    J Hepatol; 2023 Jul; 79(1):141-149. PubMed ID: 36906109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined hepatocellular cholangiocarcinoma: Controversies to be addressed.
    Wang AQ; Zheng YC; Du J; Zhu CP; Huang HC; Wang SS; Wu LC; Wan XS; Zhang HH; Miao RY; Sang XT; Zhao HT
    World J Gastroenterol; 2016 May; 22(18):4459-65. PubMed ID: 27182157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification?
    Bagante F; Ruzzenente A; Conci S; Rusev BC; Simbolo M; Campagnaro T; Pawlik TM; Luchini C; Iacono C; Scarpa A; Guglielmi A
    HPB (Oxford); 2019 Dec; 21(12):1648-1655. PubMed ID: 31122820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma.
    Balitzer D; Joseph NM; Ferrell L; Shafizadeh N; Jain D; Zhang X; Yeh M; di Tommaso L; Kakar S
    Mod Pathol; 2019 Oct; 32(10):1486-1494. PubMed ID: 31186529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
    Kendall T; Verheij J; Gaudio E; Evert M; Guido M; Goeppert B; Carpino G
    Liver Int; 2019 May; 39 Suppl 1():7-18. PubMed ID: 30882996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: 'bile ductular carcinoma'.
    Kozaka K; Sasaki M; Fujii T; Harada K; Zen Y; Sato Y; Sawada S; Minato H; Matsui O; Nakanuma Y
    Histopathology; 2007 Sep; 51(3):390-400. PubMed ID: 17553067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma.
    Rhee H; Ko JE; Chung T; Jee BA; Kwon SM; Nahm JH; Seok JY; Yoo JE; Choi JS; Thorgeirsson SS; Andersen JB; Lee HS; Woo HG; Park YN
    Liver Int; 2018 Jan; 38(1):113-124. PubMed ID: 28608943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma.
    Aishima S; Asayama Y; Taguchi K; Sugimachi K; Shirabe K; Shimada M; Sugimachi K; Tsuneyoshi M
    Mod Pathol; 2002 Nov; 15(11):1181-90. PubMed ID: 12429797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss.
    Misumi K; Hayashi A; Shibahara J; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M
    Histopathology; 2017 Apr; 70(5):766-774. PubMed ID: 27864835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance.
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2017 Feb; 70(3):423-434. PubMed ID: 27634656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma.
    Itoyama M; Hata M; Yamanegi K; Yamada N; Ohyama H; Hirano H; Terada N; Nakasho K
    Med Mol Morphol; 2012 Dec; 45(1):7-13. PubMed ID: 22431178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
    An J; Kim D; Oh B; Oh YJ; Song J; Park N; Kim HI; Kang HJ; Oh JH; Kim W; Lee E; Sung CO; Song GW; Kim DG; Yu E; Letouzé E; Zucman-Rossi J; Lee HC; Shim JH
    Hepatology; 2022 Apr; 75(4):997-1011. PubMed ID: 34478159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ubiquitin-specific protease 14 expression associated with intrahepatic cholangiocarcinoma cell differentiation.
    Chuensumran U; Saelee P; Punyarit P; Wongkham S; Pairojkul C; Chauin S; Petmitr S
    Asian Pac J Cancer Prev; 2011; 12(3):775-9. PubMed ID: 21627382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Novel Approach to Quantify Heterogeneity of Intrahepatic Cholangiocarcinoma: The Hidden-Genome Classifier.
    Song Y; Boerner T; Drill E; Shin P; Kumar S; Sigel C; Cercek A; Kemeny N; Abou-Alfa G; Iacobuzio-Donahue C; Cowzer D; Schultz N; Walch H; Balachandran V; Groot Koerkamp B; Kingham P; Soares K; Wei A; D'Angelica M; Drebin J; Chandwani R; Harding JJ; Jarnagin W
    Clin Cancer Res; 2024 Aug; 30(16):3499-3511. PubMed ID: 38864854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The mode of tumour progression in combined hepatocellular carcinoma and cholangiocarcinoma: an immunohistochemical analysis of E-cadherin, alpha-catenin and beta-catenin.
    Asayama Y; Taguchi Ki K; Aishima Si S; Nishi H; Masuda K; Tsuneyoshi M
    Liver; 2002 Feb; 22(1):43-50. PubMed ID: 11906618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.
    Akiba J; Nakashima O; Hattori S; Tanikawa K; Takenaka M; Nakayama M; Kondo R; Nomura Y; Koura K; Ueda K; Sanada S; Naito Y; Yamaguchi R; Yano H
    Am J Surg Pathol; 2013 Apr; 37(4):496-505. PubMed ID: 23388123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.